Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.77 USD
+0.20 (5.60%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVIR 3.77 +0.20(5.60%)
Will AVIR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
Other News for AVIR
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
Atea presents initial Phase 2 data for bemnifosbuvir, ruzasvir combination
Atea Pharmaceuticals: Sell Rating Amidst Uncertainty and Upcoming Trial Catalysts
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference